The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
 
Mark Andrew Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Mylan; Sanofi
 
Mia C. Weiss
No Relationships to Disclose
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Michael J Wagner
Consulting or Advisory Role - AADi; Adaptimmune; Deciphera; Epizyme
Research Funding - Adaptimmune (Inst); Athenex (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Presage Biosciences (Inst)
Travel, Accommodations, Expenses - Epizyme
 
Seth Pollack
Consulting or Advisory Role - AADi; Apexigen; Bayer; Daichii Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Obsidian Therapeutics; Sensei Biotherapeutics; T-Knife
Speakers' Bureau - Deciphera
Research Funding - Obsidian Therapeutics (Inst)
 
Edwin Choy
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Epizyme
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Andrew J. Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Lilly; Mundipharma; SERVIER
Research Funding - AADi (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Breelyn A. Wilky
Consulting or Advisory Role - Adaptimmune; Adcendo; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Agenus; Exelixis
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Lara E. Davis
Consulting or Advisory Role - Daiichi Sankyo; Regeneron; SpringWorks Therapeutics
Research Funding - Bayer (Inst); BTG (Inst); Eisai (Inst); Novartis (Inst)
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; NanoCarrier; SpringWorks Therapeutics
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03